Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 501–600 of 1,052
Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
Pisaniello, A. D., Psaltis, P. J., King, P. M., Liu, G., Gibson, R. A., Tan, J. T. M., Duong, M., Nguyen, T., Bursill, C. A., Worthley, M. I., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.003 · Cited by 64
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 57
The effects of omega-3 fatty acids in type 2 diabetes: A systematic review and meta-analysis
Xiao, Y., Zhang, Q., Liao, X., Elbelt, U., & Weylandt, K. H. (2022) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102456 · Cited by 50
2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
Zeitouni, M., Sabouret, P. F., Kernéis, M., Silvain, J., Collet, J., Bruckert, É., & Montalescot, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa077 · Cited by 61
Sherratt, S. C. R., Dawoud, H., Bhatt, D. L., Malinski, T., & Mason, R. P. (2021) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102337 · Cited by 49
Self-citationOmega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
Bhat, S. Z., Sarkar, S., Zaffar, D., Dandona, P., & Kalyani, R. R. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01831-0 · Cited by 57
Alfaddagh, A., Elajami, T. K., Saleh, M., Mohebali, D., Bistrian, B. R., & Welty, F. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.04.213 · Cited by 50
Sheikh, O., Hei, A. V., Battisha, A., Hammad, T., Pham, S. V., & CHILTON, R. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0887-0 · Cited by 58
Huang, C., Chang, M.-T., Leu, H., Yin, W., Tseng, W.-K., Wu, Y., Lin, T., Yeh, H., Chang, K., Wang, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65014-z · Cited by 57
Chen, G., Arthur, R., Qin, L.-Q., Chen, L., Mei, Z., Zheng, Y., Li, Y., Wang, T., Rohan, T. E., & Qi, Q. (2021) · Diabetes Care · doi:10.2337/dc20-2328 · Cited by 58
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 53
Chait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 58
Information and consensus document for the detection and management of chronic kidney disease
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Escalada, J., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.07.003 · Cited by 82
Wang, K., Wang, R., Yang, J., Liu, X., Shen, H., Sun, Y., Zhou, Y., Fang, Z. A., & Ge, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913869 · Cited by 57
German, C. A., Baum, S. J., Ferdinand, K. C., Gulati, M., Polonsky, T. S., Toth, P. P., & Shapiro, M. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100432 · Cited by 60
Lee, S. J., Kim, S.-E., Go, T.-H., Kang, D. R., Jeon, H.-S., Kim, Y.-I., Cho, D.-H., Park, Y. J., Lee, J.-H., Lee, J.-W., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad036 · Cited by 48
Barrea, L., Vetrani, C., Verde, L., Frías-Toral, E., Ceriani, F., Cernea, S., Docimo, A., Graziadio, C., Tripathy, D., Savastano, S., et al. (2023) · Antioxidants · doi:10.3390/antiox12040904 · Cited by 61
Omega-3 fatty acid biomarkers and incident atrial fibrillation
Qian, F., Tintle, N., Jensen, P. N., Lemaitre, R. N., Imamura, F., Feldreich, T. R., Nomura, S. O., Guan, W., Laguzzi, F., Kim, E., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.024 · Cited by 49
Optimizing Management of Stable Angina
Montone, R. A., Rinaldi, R., Niccoli, G., Andò, G., Gragnano, F., Piccolo, R., Pelliccia, F., Moscarella, E., Zimarino, M., Fabris, E., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.015 · Cited by 55
Wang, J., Wu, Q., Wang, X., Liu, H., Chen, M., Xu, L. N., Zhang, Z., Li, K., Li, W., & Zhong, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01229-z · Cited by 55
Serini, S., Cassano, R., Trombino, S., & Calviello, G. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s197499 · Cited by 52
Darwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 56
Hypertriglyceridemia: new approaches in management and treatment
Wolska, A., Yang, Z.-H., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 49
Toh, E. M. S., Lim, A. Y. L., Ming, C., Yeo, L. L. L., Sia, C., Tan, B. W. Q., Leow, A. S., Ho, J. S. Y., Chan, B., Sharma, V. K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05467-6 · Cited by 57
Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
Nakamura, M. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12568 · Cited by 61
DiNicolantonio, J. J., & OKeefe, J. (2019) · Open Heart · doi:10.1136/openhrt-2019-001011 · Cited by 48
Miller, M. J., Ballantyne, C. M., Bays, H. E., Granowitz, C. B., Doyle, R. T., Juliano, R. A., & Philip, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.057 · Cited by 52
Self-citationBerman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
Duffy, E. Y., Ashen, M. D., Blumenthal, R. S., Davis, D. M., Gulati, M., Blaha, M. J., Michos, E. D., Nasir, K., & Cainzos‐Achirica, M. (2021) · Clinical Cardiology · doi:10.1002/clc.23555 · Cited by 58
Drapkina, O. M., Karamnova, N. S., Васильевна, К. А., Gornyi, B., Дадаева, В. А., Drozdova, L. Y., Yeganyan, R. A., Олеговна, Е. С., Izmailova, O. V., Lavrenova, Е. A., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2952 · Cited by 64
Hilleman, D. E., Wiggins, B. S., & Bottorff, M. B. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01211-1 · Cited by 46
Kalra, D. K., Vijayaraghavan, K., Sikand, G., Desai, N. R., Joshi, P. H., Mehta, A., Karmally, W., Vani, A. K., Sitafalwalla, S. J., Puri, R., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.03.007 · Cited by 50
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01525-5 · Cited by 57
Chow, S. L., Bozkurt, B., Baker, W. L., Bleske, B. E., Breathett, K. K., Fonarow, G. C., Greenberg, B., Khazanie, P., Leclerc, J., Morris, A. A., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001110 · Cited by 61
Update of the risk assessment of mineral oil hydrocarbons in food
(CONTAM), E. P. O. C. I. T. F. C., Schrenk, D., Bignami, M., Bodin, L., del Mazo, J., Grasl‐Kraupp, B., Högstrand, C., Hoogenboom, L. A. P., Leblanc, J., Nebbia, C., et al. (2023) · EFSA Journal · doi:10.2903/j.efsa.2023.8215 · Cited by 74
Zhang, Y., Sun, Y., Yu, Q., Song, S., Brenna, J. T., Shen, Y., & Ye, K. (2023) · eLife · doi:10.7554/elife.90132 · Cited by 107
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 60
Early-onset atherosclerotic cardiovascular disease
Mousavi, I., Suffredini, J. M., Virani, S. S., Ballantyne, C. M., Michos, E. D., Misra, A., Saeed, A., & Jia, X. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae240 · Cited by 62
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease
Marquis‐Gravel, G., Roe, M. T., Harrington, R. A., Muñoz, D., Hernandez, A. F., & Jones, W. S. (2019) · Circulation · doi:10.1161/circulationaha.119.040205 · Cited by 51
Agrawal, H., Choy, H.-H., Liu, J., Auyoung, M., & Albert, M. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.313608 · Cited by 62
Khoury, M., Bigras, J., Cummings, E. A., Harris, K. C., Hegele, R. A., Henderson, M., Morrison, K. M., St‐Pierre, J., Wong, P. D., & McCrindle, B. W. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.002 · Cited by 63
Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022937 · Cited by 38
Self-citationLipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 62
The Effects of Omega 3 and Omega 6 Fatty Acids on Glucose Metabolism: An Updated Review
Egalini, F., Guardamagna, O., Gaggero, G., Varaldo, E., Giannone, B., Beccuti, G., Benso, A. S., & Broglio, F. (2023) · Nutrients · doi:10.3390/nu15122672 · Cited by 58
O’Keefe, J. H., Tintle, N. L., Harris, W. S., O’Keefe, E. L., Sala-Vila, A., Attia, J., Garg, G. M., Hure, A., Bork, C. S., Schmidt, E. B., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.044281 · Cited by 46
First myocardial infarction: risk factors, symptoms, and medical therapy
Nurmohamed, N. S., Ngo‐Metzger, Q., Taub, P. R., Ray, K. K., Figtree, G. A., Bonaca, M. P., Hsia, J. A., Angadageri, S., Earls, J. P., Rodríguez, F., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf390 · Cited by 54
Self-citationLai, H. T. M., Otto, M. C. D. O., Lee, Y., Wu, J. H. Y., Song, X., King, I. B., Psaty, B. M., Lemaître, R. N., McKnight, B., Siscovick, D. S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012881 · Cited by 53
Mahé, G., Böge, G., Bura-Rivière, A., Chakfé, N., Constans, J., Gouëffic, Y., Lacroix, P., Hello, C. L., Pernod, G., Pérez‐Martin, A., et al. (2020) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2020.11.011 · Cited by 58
Sigaux, J., Mathieu, S., Nguyen, Y., Sanchez, P., Letarouilly, J.-G., Soubrier, M., Czernichow, S., Flipo, R., Sellam, J., & Daïen, C. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02781-2 · Cited by 63
Drexel, H., LARCHER, B., MADER, A., Vonbank, A., Heinzle, C. F., Moser, B., Zanolin-Purin, D., & Saely, C. H. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.010 · Cited by 46
Yan, J., Liu, M., Yang, D., Zhang, Y., & An, F. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07379-z · Cited by 41
Huang, L., Zhang, F., Xu, P., Zhou, Y., Liu, Y., Zhang, H., Tan, X., Ge, X., Xu, Y., Guo, M., et al. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.04.009 · Cited by 49
Yang, Y., Xia, Y., Zhang, B., Li, D., Yan, J., Yang, J., Sun, J. P., Cao, H., Wang, Y., & Zhang, F. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1166702 · Cited by 49
Tułowiecka, N., Kotlęga, D., Prowans, P., & Szczuko, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207628 · Cited by 50
O’Connell, T. D., Mason, R. P., Budoff, M. J., Návar, A. M., & Shearer, G. C. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa115 · Cited by 47
Zhu, X., Li, X., Xu, R., & Wang, T. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa985 · Cited by 44
Current Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 48
Bashir, B., Ho, J. H., Downie, P., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 52
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 49
Katz, D. H., & Gavin, M. C. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201908060 · Cited by 55
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Wiciński, M., Górski, K. M., Wódkiewicz, E., Walczak, M., Nowaczewska, M., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072275 · Cited by 53
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease
Kou, M., Ding, N., Ballew, S. H., Salameh, M. J., Martin, S. S., Selvin, E., Heiss, G., Ballantyne, C. M., Matsushita, K., & Hoogeveen, R. C. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315828 · Cited by 44
Self-citationJohansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315639 · Cited by 45
EPA’s pleiotropic mechanisms of action: a narrative review
Nelson, J. R., Budoff, M. J., Wani, O. R., Le, V. T., Patel, D. K., Nelson, A., & Nemiroff, R. L. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1921491 · Cited by 49
Omega-3 fatty acids attenuate cardiovascular effects of short-term exposure to ambient air pollution
Chen, H., Zhang, S., Shen, W., Salazar, C., Schneider, A. E., Wyatt, L. H., Rappold, A. G., Díaz-Sánchez, D., Devlin, R. B., Samet, J. M., et al. (2022) · Particle and Fibre Toxicology · doi:10.1186/s12989-022-00451-4 · Cited by 48
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 43
Self-citationRevisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis
Jalil, A., Bourgeois, T., Ménégaut, L., Lagrost, L., Thomas, C., & Masson, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153787 · Cited by 45
Hollan, I., Ronda, N., Dessein, P. H., Agewall, S., Karpouzas, G. A., Tamargo, J. L., Niessner, A., Savarese, G., Rosano, G. M. C., Kaski, J. C., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz033 · Cited by 48
Ray, K. K., Del Prato, S., Müller-Wieland, D., Cariou, B., Colhoun, H. M., Tinahones, F. J., Domenger, C., Letierce, A., Mandel, J., Samuel, R., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0951-9 · Cited by 43
Kukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Балахонова, Т. В., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 51
Schaller, M. S., Chen, M., Colas, R. A., Sorrentino, T. A., Lazar, A., Grenon, S. M., Dalli, J., & Conte, M. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016113 · Cited by 48
the DARWIN-T2D Network of the Italian Diabetes Society, Morieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01164-8 · Cited by 51
Yamaguchi, A. A., Stanger, L., Freedman, C. J., Standley, M. S., Hoang, T., Adili, R., Tsai, W., van Hoorebeke, C., Holman, T. R., & Holinstat, M. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15184 · Cited by 50
Lakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz329 · Cited by 42
Self-citationCalcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 46
Yang, Z., Nill, K., Takechi‐Haraya, Y., Playford, M. P., Nguyen, D., Yu, Z., Pryor, M., Tang, J., Rojulpote, K. V., Mehta, N. N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158385 · Cited by 48
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease
Ganda, O. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000875 · Cited by 46
Yang, Z., Amar, M. J., Sampson, M. L., Courville, A. B., Sorokin, A. V., Gordon, S. M., Aponte, A. M., Stagliano, M. S., Playford, M. P., Fu, Y., et al. (2020) · Nutrients · doi:10.3390/nu12030749 · Cited by 43
Ding, L., Zhang, L., Shi, H.-H., Wang, C., Jiang, X., Xue, C., Yanagita, T., Zhang, T., & Wang, Y.-M. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b08296 · Cited by 44
The Potential Uses of Omega-3 Fatty Acids in Dermatology: A Review
Thomsen, B. J., Chow, E. Y., & Sapijaszko, M. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420929925 · Cited by 52
Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk
Welty, F. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000689 · Cited by 49
Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
Penson, P. E., & Banach, M. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.015 · Cited by 43
Watanabe, Y., & Tatsuno, I. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1863784 · Cited by 46
Mason, R. P., & Eckel, R. H. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.014 · Cited by 42
Nishizaki, Y., Miyauchi, K., Iwata, H., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2022.11.008 · Cited by 40
Chapman, M. J., & Mason, R. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108237 · Cited by 45
Zhang, J., Chen, G., Xia, H., Wang, X., Wang, C., Cai, M., Gao, Y., Lip, G. Y. H., & Lin, H. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.132114 · Cited by 45
Dietary Composition and Cardiovascular Risk: A Mediator or a Bystander?
Korakas, E., Dimitriadis, G., Raptis, A. E., & Lambadiari, V. (2018) · Nutrients · doi:10.3390/nu10121912 · Cited by 52
The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway
Aquila, G., Marracino, L., Martino, V., Calabria, D., Campo, G. C., Caliceti, C., & Rizzo, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5470470 · Cited by 47
Sato, T., Horikawa, M., Takei, S., Yamazaki, F., Ito, T. K., Kondo, T., Sakurai, T., Kahyo, T., Ikegami, K., Sato, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313093 · Cited by 42
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Drenjančević, I., & Pitha, J. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042104 · Cited by 236
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2022) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102450 · Cited by 43
Self-citationSharma, G. V., Martin, S. S., & Blumenthal, R. S. (2020) · JAMA · doi:10.1001/jama.2020.22387 · Cited by 43
The Fibrates Story — A Tepid End to a PROMINENT Drug
Virani, S. S. (2022) · New England Journal of Medicine · doi:10.1056/nejme2213208 · Cited by 40
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 40
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.